These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8922203)

  • 41. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
    Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
    Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer.
    Bokemeyer C; Beyer J; Metzner B; Ruther U; Harstrick A; Weissbach L; Kohrmann U; Verbeek W; Schmoll HJ
    Ann Oncol; 1996 Jan; 7(1):31-4. PubMed ID: 9081388
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
    Hainsworth JD; Greco FA
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.
    McMeekin DS; Sill MW; Walker JL; Moore KN; Waggoner SE; Thaker PH; Rizack T; Hoffman JS; Fracasso PM
    Gynecol Oncol; 2015 Jul; 138(1):36-40. PubMed ID: 25958319
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
    Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J
    Breast Cancer Res Treat; 2008 Mar; 108(2):241-50. PubMed ID: 17476588
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
    Klaassen U; Wilke H; Seeber S
    J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II trial of 3-h infusion of paclitaxel in patients with adenocarcinoma of endometrium: Japanese Multicenter Study Group.
    Hirai Y; Hasumi K; Onose R; Kuramoto H; Kuzuya K; Hatae M; Ochiai K; Nozawa S; Noda K
    Gynecol Oncol; 2004 Aug; 94(2):471-6. PubMed ID: 15297190
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
    Adamo V; Ferraro G; Pergolizzi S; Sergi C; Laudani A; Settineri N; Alafaci E; Scimone A; Spano F; Spitaleri G
    Oral Oncol; 2004 May; 40(5):525-31. PubMed ID: 15006626
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
    Markman M; Liu PY; Wilczynski S; Monk B; Copeland LJ; Alvarez RD; Jiang C; Alberts D; ;
    J Clin Oncol; 2003 Jul; 21(13):2460-5. PubMed ID: 12829663
    [TBL] [Abstract][Full Text] [Related]  

  • 50. One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicentre, phase II trial.
    Hainsworth JD; Urba WJ; Hon JK; Thompson KA; Stagg MP; Hopkins LG; Thomas M; Greco FA
    Eur J Cancer; 1998 Apr; 34(5):654-8. PubMed ID: 9713269
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen.
    Murad AM; Petroianu A; Guimaraes RC; Aragao BC; Cabral LO; Scalabrini-Neto AO
    Am J Clin Oncol; 1999 Dec; 22(6):580-6. PubMed ID: 10597742
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Paclitaxel (Taxol) as salvage therapy for relapsed ovarian cancer.
    Planner RS; Allen DG; Brand AH; Grant PT; Toner GC; Sykes PH
    Aust N Z J Obstet Gynaecol; 1996 May; 36(2):168-70. PubMed ID: 8798307
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer.
    Georgiadis MS; Schuler BS; Brown JE; Kieffer LV; Steinberg SM; Wilson WH; Takimoto CH; Kelley MJ; Johnson BE
    J Clin Oncol; 1997 Feb; 15(2):735-43. PubMed ID: 9053499
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Phase I/II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Tienghi A; Ravaioli A; Casadei Giunchi D; Gentile A; Salzano E
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):19-23. PubMed ID: 8629031
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study.
    Ko YJ; Canil CM; Mukherjee SD; Winquist E; Elser C; Eisen A; Reaume MN; Zhang L; Sridhar SS
    Lancet Oncol; 2013 Jul; 14(8):769-76. PubMed ID: 23706985
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial.
    Mavroudis D; Kourousis C; Androulakis N; Kalbakis K; Agelaki S; Kakolyris S; Souglakos J; Sarra E; Vardakis N; Hatzidaki D; Sarmonis G; Georgoulias V
    Am J Clin Oncol; 2000 Aug; 23(4):341-4. PubMed ID: 10955859
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Australasian multicentre phase II study of paclitaxel (Taxol) in relapsed ovarian cancer.
    Phillips KA; Friedlander M; Olver I; Evans B; Smith J; Fitzharris B; McCrystal M; Joughin J; Bishop J
    Aust N Z J Med; 1995 Aug; 25(4):337-43. PubMed ID: 8540875
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer.
    Livingston RB; Ellis GK; Gralow JR; Williams MA; White R; McGuirt C; Adamkiewicz BB; Long CA
    J Clin Oncol; 1997 Apr; 15(4):1395-400. PubMed ID: 9193331
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.
    Frasci G; Comella P; D'Aiuto G; Budillon A; Barbarulo D; Thomas R; Capasso I; Casaretti R; Daponte A; Caponigro F; Gravina A; Maiorino L; Caratení G; Gentile A; Comella G
    Breast Cancer Res Treat; 1998 May; 49(1):13-26. PubMed ID: 9694607
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Activity of paclitaxel by three-hour infusion in Asian patients with metastatic undifferentiated nasopharyngeal cancer.
    Au E; Tan EH; Ang PT
    Ann Oncol; 1998 Mar; 9(3):327-9. PubMed ID: 9602268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.